ADA 2021: AMPLITUDE-O Demonstrates Cardiovascular and Renal Benefits of Efpeglenatide in High-Risk Type 2 Diabetes
Benefits were independent of concomitant use of SGLT2 inhibitors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.